Evolent Health, Inc.
Close on Oct 19, 2026
- Market cap
- $504.19M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $652.52M | $-0.25 | $0.02 |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $496.25M | $-0.24 | $-0.02 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 24, 2026 | During market hours | $468.72M | $-3.84 | $0.08 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | During market hours | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | During market hours | $444.33M | $-0.44 | $-0.10 |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | During market hours | $483.65M | $-0.63 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 20, 2025 | During market hours | $646.50M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | During market hours | $621.40M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 22, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| cash for capitalized software development | 2026 | $25.00M to $30.00M | Maintained |
| Adjusted EBITDA rangenon-GAAP | 2026 | $120.00M to $135.00M | Narrowed |
| revenue guidance range | 2026 | $2.60B to $2.70B | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Evolent Health filed with the SEC
Evolent Announces Second Quarter 2026 Results
Results of operations · EX-99.1 to Form 8-K
Evolent Announces First Quarter 2026 Results
Results of operations · EX-99.1 to Form 8-K
Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results
Results of operations · EX-99.1 to Form 8-K
Evolent Announces Third Quarter 2025 Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Evolent Announces Strategic Divestiture of its Value-Based Primary Care Business, Evolent Care Partners
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Evolent Health, Inc. Announces Pricing of Oversubscribed and Upsized $145.0 Million of Convertible Senior Notes Due 2031
Other events · EX-99.1 to Form 8-K
Evolent Health, Inc. Announces Proposed Offering of $140.0 Million of Convertible Senior Notes Due 2031 to Repurchase
Other events · EX-99.1 to Form 8-K
Evolent Announces Second Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
Evolent reiterates Q2 and full year guidance for Adjusted EBITDA
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Evolent Announces First Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
Evolent names Shawn Guertin as new independent nominee for election to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Evolent Announces Fourth Quarter and Full Year 2024 Results
Results of operations · EX-99.1 to Form 8-K
Evolent Health Announces Changes to Board of Directors
Material agreement · Executive or director change · Other events · EX-99.1 to Form 8-K
Investor Presentation 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Evolent Announces Third Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K
Evolent Announces Second Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K
Evolent signs agreement to acquire artificial intelligence utilization management products and team from Machinify
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
44th Annual William Blair Growth Stock Conference June 4, 2024
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Evolent Announces First Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K
Evolent Announces Fourth Quarter and Full Year 2023 Results
Results of operations · EX-99.1 to Form 8-K
Evolent Adds Russell Glass, Headspace CEO, to Board of Directors
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
J.P. Morgan 42nd Annual Healthcare Conference January 9, 2024
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Evolent Health, Inc. Announces Pricing of $350.0 Million of Convertible Senior Notes Due 2029 to Pay Down Senior Term Loan
Other events · EX-99.1 to Form 8-K
Evolent Health, Inc. Announces Proposed Offering of $350.0 Million of Convertible Senior Notes Due 2029 to Pay Down Senior Term Loan
Other events · EX-99.1 to Form 8-K
(A Business of Magellan Health, Inc.)
Other events · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS
Other events · EX-99.2 to Form 8-K
Evolent Announces Third Quarter 2023 Results
Results of operations · EX-99.1 to Form 8-K
(A Business of Magellan Health, Inc.)
Other events · EX-99.1 to Form 8-K/A
UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS
Other events · EX-99.3 to Form 8-K/A
Evolent Announces Second Quarter 2023 Results
Results of operations · Other events · EX-99.1 to Form 8-K
Evolent welcomes Toyin Ajayi to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
o o o o o o o
Regulation FD disclosure · EX-99.1 to Form 8-K
Evolent Health Announces First Quarter 2023 Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Evolent Health Names New Independent Nominee for Election to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Evolent Health Announces Fourth Quarter and Full Year 2022 Results
Results of operations · EX-99.1 to Form 8-K
1 41st Annual J.P. Morgan Healthcare Conference Investor Presentation January 11, 2023 Exhibit 99.1
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
EVOLENT HEALTH ANNOUNCES ACQUISITION OF SPECIALTY ASSET NIA AND STRATEGIC PARTNERSHIP WITH CENTENE
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Confidential – Do Not Distribute1 Evolent Health, Inc. Supplemental Investor Presentation November 9, 2022 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Evolent Health Announces Third Quarter 2022 Results
Results of operations · EX-99.1 to Form 8-K